MedTrace Logo

Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

NCT03724968 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2021-04-20

Study results available
· View outcomes & findings →

Summary

This is an open-label, non-randomized two arm Phase 2 study of intravenous nivolumab plus intravenous ipilimumab or intravenous relatlimab in patients with metastatic melanoma stratified by MHC-II expression.

Conditions

Interventions

DRUG

Nivolumab

Nivolumab will be given by vein on day 1 of each cycle.

DRUG

Relatlimab

Relatlimab will be given by vein on day 1 of each 28-day cycle

DRUG

Ipilimumab

Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).

Sponsors & Collaborators

Principal Investigators

  • Elizabeth Davis, MD · Vanderbilt Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-17
Primary Completion
2020-05-28
Completion
2020-05-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03724968 on ClinicalTrials.gov